Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL(2024)
摘要
Objective To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.Methods We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.Results The mean Timed-25-Foot Walk score was reduced from 14.8 (+/- 2.4) to 11.3 (+/- 1.9) seconds (p = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (+/- 3.5) to 31.4 (+/- 3.2) (p = 0.004).Conclusion Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.
更多查看译文
关键词
Fampridine,neuromyelitis optica spectrum disorder,neuromyelitis optica
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要